Author(s): Yap TA, Carden CP, Kaye SB
Abstract Share this page
Abstract Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease. In an age when great advances have been made in understanding the genetics and molecular biology of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer. Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine. TRIAL REGISTRATION: ClinicalTrials.gov NCT00429793 NCT00523432 NCT00610714 NCT00628251 NCT00753545.
This article was published in Nat Rev Cancer
and referenced in Journal of Clinical & Experimental Pharmacology